GSK completes transaction with Pfizer
admin 1st August 2019 Uncategorised 0GSK has a controlling equity interest of 68% and Pfizer has an equity interest of 32% in the venture. More: GSK completes transaction with Pfizer Source: News
read moreGSK has a controlling equity interest of 68% and Pfizer has an equity interest of 32% in the venture. More: GSK completes transaction with Pfizer Source: News
read moreThe success marks the second Phase III clinical trial in which Kisqali met overall survival. More: Kisqali success continues with positive late-stage trial results Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals